Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation
- PMID: 17622782
- DOI: 10.1159/000105160
Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation
Abstract
Background: Recently, mutations in LRRK2 encoding the protein dardarin have been linked to an autosomal dominant form of parkinsonism.
Objective: To identify mutations causing Parkinson's disease (PD) in a cohort of North Americans with familial PD.
Methods: We sequenced exons 1-51 of LRRK2 in 79 unrelated North American PD patients reporting a family history of the disease.
Results: One patient had a missense mutation (Thr2356Ile) while two others had the common Gly2019Ser mutation. In addition, 1 patient had a 4-bp deletion in close proximity to the exon 19 splice donor (IVS20+4delGTAA) that in vitro abrogates normal splicing.
Conclusions: Our observations in the 79 North American patients indicate that mutations in LRRK2 are associated with approximately 5% of PD cases with a positive family history. The results also show that G2019S represents approximately half of the LRRK2 mutations in United States PD cases with a family history of the disease. We have identified two novel mutations in LRRK2.
Copyright (c) 2007 S. Karger AG, Basel.
Similar articles
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
-
Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.Parkinsonism Relat Disord. 2013 Oct;19(10):897-900. doi: 10.1016/j.parkreldis.2013.05.003. Epub 2013 May 28. Parkinsonism Relat Disord. 2013. PMID: 23726462
-
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Neurology. 2007 Oct 16;69(16):1595-602. doi: 10.1212/01.wnl.0000277637.33328.d8. Neurology. 2007. PMID: 17938369
-
LRRK2 gene in Parkinson disease: mutation analysis and case control association study.Neurology. 2005 Sep 13;65(5):696-700. doi: 10.1212/01.wnl.0000167552.79769.b3. Neurology. 2005. PMID: 16157901
-
LRRK2 and Parkinson disease.Arch Neurol. 2010 May;67(5):542-7. doi: 10.1001/archneurol.2010.79. Arch Neurol. 2010. PMID: 20457952 Review.
Cited by
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
-
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.J Neurochem. 2016 Oct;139 Suppl 1(Suppl 1):59-74. doi: 10.1111/jnc.13593. Epub 2016 Apr 18. J Neurochem. 2016. PMID: 27090875 Free PMC article. Review.
-
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.Hum Mutat. 2010 Jul;31(7):763-80. doi: 10.1002/humu.21277. Hum Mutat. 2010. PMID: 20506312 Free PMC article. Review.
-
LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.Mov Disord. 2009 May 15;24(7):1034-41. doi: 10.1002/mds.22514. Mov Disord. 2009. PMID: 19343804 Free PMC article.
-
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. J Neurosci Res. 2009. PMID: 19025767 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials